44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

President Donald Trump at the White House on Thursday. (Evan Vucci / AP) President Donald Trump will announce a plan to lower U.S. prescription drug costs by tying the amount the government pays for ...

SEOUL, May 15 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump's executive order ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. David Mitchell, president and founder of Patients for Affordable ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

Biosimilars have yet to achieve their main purpose: to reduce the costs of complex biological drugs, as generics do for small molecules. Multiple barriers, from development costs to the contracting ...

WASHINGTON (Reuters) -Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss drugs, especially those bought online, outgoing U.S.

CHICAGO — A big breakthrough in cancer research and it’s all due to a tiny structure. The science was developed in Chicago. They took an old drug and made it better. The restructured drug appears to ...

SEOUL, May 15 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump's executive order ...